Biography
Specialties
Monica Kraft, MD
PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
PROFESSOR | Medicine, Pulmonary, Critical Care and Sleep Medicine
Are you a patient?
View my
Are you a patient?
View my
Education
MD, njms
Residency, Internal Medicine, Harbor/UCLA Medical Center
Fellowship, Pulmonary Disease, University of Colorado at Denver
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kraft during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- RaeSedo Inc
Consulting:
- AstraZeneca
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- RaeSedo Inc
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- AstraZeneca
- Chiesi Pharmaceuticals
- sanofi-aventis
Royalty Payments:
- RaeSedo, Inc
Scientific Advisory Board:
- RaeSedo Inc
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- RaeSedo Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kraft during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- RaeSedo Inc
Consulting:
- AstraZeneca
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- RaeSedo Inc
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- AstraZeneca
- Chiesi Pharmaceuticals
- sanofi-aventis
Royalty Payments:
- RaeSedo, Inc
Scientific Advisory Board:
- RaeSedo Inc
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- RaeSedo Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.